Volition Publishes First Peer-Reviewed Paper on Capture-Seq™ Liquid Biopsy Technology
VolitionRx Limited has published its first peer-reviewed scientific paper detailing its new Capture-Seq™ liquid biopsy technology. The technology targets early cancer detection and MRD monitoring, addressing a $36 billion market.
VolitionRx Limited (NYSE AMERICAN: VNRX) has published its first peer-reviewed scientific paper detailing its new Capture-Seq™ liquid biopsy technology. The company believes the technology has the potential to transform early cancer detection and minimal residual disease (MRD) monitoring, a market estimated at $36 billion.
The publication provides scientific validation for the Capture-Seq™ technology, which utilizes epigenetics to detect cancer-related DNA markers in a blood sample. Volition stated it is in active discussions with global diagnostic leaders to accelerate the commercialization of the technology.
The company aims to introduce a new blood-based testing method. This is expected to offer a faster and less invasive way to diagnose and monitor various cancer types. The peer-reviewed publication represents a significant step toward broader adoption and clinical use.
Volition anticipates the technology will improve patient outcomes and facilitate personalized treatment strategies. Capture-Seq™ may potentially identify cancer at its earliest stages, when treatment is often most effective.